Cardiology
Service
Pfizer (United States)
Nueva York, Estados UnidosPublications in collaboration with researchers from Pfizer (United States) (10)
2024
-
Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy
European Journal of Heart Failure, Vol. 26, Núm. 3, pp. 612-615
-
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy
ESC Heart Failure
-
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy
Circulation: Heart Failure, Vol. 17, Núm. 7, pp. e011548
-
The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary
Future Cardiology
2020
-
Gender differences in health-related quality of life in patients with systolic heart failure: Results of the vida multicenter study
Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-15
2017
-
Cardiovascular efficacy and safety of bococizumab in high-risk patients
New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539
2014
-
Sirolimus conversion after heart transplant: Risk factors for acute rejection and predictors of renal function response
American Journal of Transplantation, Vol. 14, Núm. 9, pp. 2048-2054
2012
-
Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency
American Journal of Transplantation, Vol. 12, Núm. 9, pp. 2487-2497
2009
-
Biology of BMP signalling and cancer
Clinical and Translational Oncology, Vol. 11, Núm. 3, pp. 126-137
-
Notch signalling in cancer stem cells
Clinical and Translational Oncology, Vol. 11, Núm. 1, pp. 11-19